Phase 2 N=51 Ziprasidone in the Psychosis Prodrome
Psychosis Prodrome
Primary: Conversion to Psychosis — 1; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)
Obsessive-Compulsive Disorder
Primary: Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale — 5 participants
Phase 2 N=33 Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery
Lung Cancer
Primary: Primary Tumor Control at 2 Years — 96.2 percentage of patients
Phase 2 N=15 Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)
Obsessive-Compulsive Disorder
Primary: Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale. — 0; 5 participants
Phase 2 N=29 Trial of Antimycobacterial Therapy in Sarcoidosis
Sarcoidosis
Primary: Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions — -8.4…
Phase 2 N=155 Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
Smoking Cessation
Primary: Change From Baseline in the Average Number of Cigarettes Smoked Per Day — 36; 45; 36; 28 participants
Phase 2 N=190 Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
Meningococcal Disease
Primary: 1. Percentages of Subjects With HT-hSBA (High-throughput Human Serum Bactericidal Assay) Seroresponse Against N. Meningitidis Serogroups A, C, W and Y. — 96; 94; 85; 100…
Phase 2 N=33 Safety Study of Pyridostigmine in Heart Failure
Heart Failure
Primary: Baseline Heart Rate Recovery — 32.5; 30.4 beats per minute
Phase 2 N=14 Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions
TBI · Major Depression · Other Psychiatric Disorders
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline — 29.5; 33.6 units on a scale
Phase 2 N=4 Bortezomib to Treat Significant Complication of HSCT
Allogeneic Stem Cell Transplantation · Refractory Autoimmune Cytopenia(s)
Primary: Number of Participants With Response — 3; 2; 1 participants
Phase 2 N=55 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
Recurrent Hypopharyngeal Squamous Cell Carcinoma · Recurrent Laryngeal Squamous Cell Carcinoma · Recurrent Laryngeal Verrucous Carcinoma
Primary: Mean Percent Change in p16 Methylation (% CpG Sites Methylated) in Tumor Tissue After Soy Isoflavone — 4.9 Percent change — p=<0.005
Phase 2 N=163 Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Therapy-Related Acute Myeloid Leukemia
Primary: Overall Survival (OS) Time — 9.3; 8.8 months — p=0.30
Phase 2 N=60 Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
Chemotherapy-induced Neutropenia
Primary: CTCAE Grade 3/4 Neutropenia Incidence — 18; 13; 11 participants — p=<0.05
Phase 2 N=55 FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Malignant Pleural Effusion · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Overall Response Rate (Patients That Achieve a CR or PR) — 13 participants
Phase 2 N=97 Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival (12-month Rate Reported) — 60.1; 50.8 percentage of participants — p=0.2103